Statins and HIV: how can the REPRIEVE findings be implemented in the real world?

By Liz Highleyman

Findings from the landmark REPRIEVE trial, which tested a daily statin medication for people living with HIV, were presented on Monday at the 12th International AIDS Society Conference on HIV Science (IAS 2023) and published in The New England Journal of Medicine. The results were presented at a symposium that also included a discussion of cardiovascular disease among people with HIV and the study’s implications for clinical practice.

Read the full article here.